^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-08046054

    i
    Other names: PF-08046054, SGN-PDL1V, PF08046054, SGNPDL1V, PF 08046054, SGN PDL1V
    Company:
    Pfizer
    Drug class:
    Microtubule inhibitor, PD-L1-targeted antibody-drug conjugate
    Related drugs:
    2ms
    A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=680, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    docetaxel • PF-08046054
    3ms
    A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=680, Not yet recruiting, Pfizer
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    docetaxel • PF-08046054
    6ms
    SGNPDL1V-001: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=315, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Sep 2027 --> Apr 2028 | Trial primary completion date: Sep 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PF-08046054
    7ms
    SGNPDL1V-001: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=315, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Nov 2028 --> Sep 2027 | Trial primary completion date: Nov 2027 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PF-08046054
    10ms
    SGNPDL1V-001: A Study of SGN-PDL1V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=315, Recruiting, Seagen Inc. | Trial completion date: Dec 2027 --> Nov 2028 | Trial primary completion date: Jul 2025 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PF-08046054
    1year
    SGNPDL1V-001: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=438, Recruiting, Seagen Inc. | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PF-08046054
    over1year
    SGNPDL1V-001: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=438, Recruiting, Seagen Inc. | N=322 --> 438
    Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • PF-08046054
    over3years
    Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress). (ASCO 2022)
    Objective response rate will be analyzed by tumor type, dose levels, and schedules. Enrollment for Part A is ongoing at sites in North America and is planned in Europe.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PF-08046054